Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medaxes Sets Out Hopes For Belgian Biosimilars Taskforce

INAMI Taskforce Met For The First Time In Late January

Executive Summary

Belgian off-patent industry association Medaxes has set out its aspirations for a new biosimilars taskforce that has been set up by local health insurance body INAMI. Data cited by the industry body shows that biosimilar penetration in Belgium is still lagging behind that of its European neighbors.

You may also be interested in...



European Biosimilars Can Benefit From Sharing Experiences

Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.

Belgium’s Medaxes Appoints New Board

Belgian industry association Medaxes has appointed a new board at the same time as revealing plans for a biosimilars awareness day in April, following in the footsteps of a recent initiative focused on generics.

Belgian Law Seeks To Tackle Shortages

Legislation that has just been adopted by the Belgian parliament is aiming to tackle shortages by requiring companies to notify local authorities of supply interruptions within three working days, as well as giving pharmacists the option to substitute equivalent alternatives to products in short supply. The new measures limit the risk of excessive sanctions for suppliers, according to local industry association Medaxes.

Related Content

Topics

UsernamePublicRestriction

Register

GB149635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel